Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RP-6306 |
Synonyms | |
Therapy Description |
RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest and apoptosis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RP-6306 | RP6306|RP 6306 | RP-6306 is a PKMYT1 inhibitor, which may decrease CDK1 phosphorylation, leading to cell cycle arrest and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FBXW7 R465H | cervical cancer | sensitive | RP-6306 | Preclinical - Cell culture | Actionable | In a preclinical study, a cervical cancer cell line harboring FBXW7 R465H demonstrated increased sensitivity to RP-6306 treatment compared to a cell line with wild-type FBXW7 in culture (PMID: 38032106). | 38032106 |
FBXW7 del | Advanced Solid Tumor | sensitive | RP-6306 | Preclinical - Cell culture | Actionable | In a preclinical study, a cell line with knockout of FBXW7 demonstrated increased sensitivity to RP-6306 treatment compared to cells with wild-type FBXW7 in culture (PMID: 38032106). | 38032106 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04855656 | Phase I | RP-6306 | Study of RP-6306 in Advanced Solid Tumors | Recruiting | USA | DNK | CAN | 0 |